China’s pharmaceutical market presents an immense opportunity for pharmaceutical companies, both from home and abroad. With a vast population, significant unmet clinical needs and a rapidly improving regulatory and market access environment, international pharmas have expanded to China to invest in this dynamic market. Over the past four decades, these companies have made substantial investments, introduced hundreds of innovative medicines and played a pivotal role in advancing the Chinese pharmaceutical industry.
This L.E.K. Consulting Special Report explores the strategic opportunities available in China for international pharmas. It explores the changing landscape of the pharmaceutical market, examining how MNCs (Multinational Corporations) have adapted to the “new normal”, fueled innovation and embraced digital transformation. Additionally, the report sheds light on China’s increasing contributions to global innovation, offering a compelling reason for international pharmas to explore partnerships and collaborations in the country.
L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2023 L.E.K. Consulting LLC
Life Sciences & Pharma
EUnetHTA 21 — Transition to EU-wide HTAs: Implications for Pharma
The LatAm Digital Landscape in Healthcare: Where Are the Opportunities Today?